drugset / Trial / NCT00673478

Tiotropium and Salmeterol PK Study in COPD Patients

NCT00673478

Phase 3 Completed 50 enrolled Boehringer Ingelheim
CrossoverTreatment

Summary

The primary objective of this study is to characterize the pharmacokinetics (i.e. systemic exposure to tiotropium and salmeterol) of tiotropium qd + salmeterol qd or bid versus tiotropium qd and salmeterol bid following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD).

Timeline

Start
2008-05
Primary completion
2009-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified
Subject Tiotropium Other / unclassified